Clinical Trial Update: Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 MATCH subprotocol (H) testing trametinib and dabrafenib for cancers with BRAF genetic alterations. The study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Lymphoma
• Multiple Myeloma
• Solid Tumor

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING